National Institute on Drug Abuse; Amended Notice of Meeting, 32713 [2017-14858]
Download as PDF
<![CDATA[
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Development, commercial
application and use of fulvestrant in
estrogen receptor positive cancers, in
combination with other products and
therapies, excluding poxvirus-based
vaccines.’’ For avoidance of doubt, the
field of use specifically excludes the use
of fulvestrant in combination with
poxvirus-based vaccines.
This technology discloses the use of
fulvestrant, an estrogen receptor
antagonist, as an immune modulating
agent that enhances the effects of
immunotherapy and/or chemotherapy
in cancer cells. Fulvestrant treatment of
mesenchymal-like lung carcinoma cells
increases immune-mediated lysis by
reversing epithelial mesenchymal
transition (EMT), potentially repairing
defective cell death mechanisms driven
by EMT, and restoring immunemediated lysis to chemo-resistant cells.
Overall, treatment of cancer cells with
fulvestrant in combination with
immunotherapy or chemotherapy agents
results in increased cancer cell death.
Although immunotherapy is leading the
charge in cancer treatments, its efficacy
is limited by patient resistance to
immunotherapy and/or nonresponsiveness. Combination therapy
with fulvestrant that enhances the
therapeutic effects of immunotherapy
and chemotherapy, is a promising
strategy to improve the clinical outcome
for patients with resistant or
unresponsive tumors.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
Dated: July 6, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–14860 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
July 27, 2017, 09:00 a.m. to July 27,
2017, 05:00 p.m., National Institutes of
Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD
20852 which was published in the
Federal Register on June 29, 2017, 82
125 FR 2017–13696.
This meeting was amended to change
the date from July 27, 2017 to July 25,
2017. The time of the meeting remains
the same. The meeting is closed to the
public.
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–14858 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Peter Tung; 240–669–5483; peter.tung@
nih.gov. Licensing information and
copies of the patent applications listed
below may be obtained by
communicating with the indicated
licensing contact at the Technology
Transfer and Intellectual Property
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD, 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Compounds That Treat Malaria and
Prevent Malaria Transmission
National Institutes of Health
AGENCY:
32713
Description of Technology
Malaria is the single leading cause of
death, especially among children, in the
developing world. Malaria is caused by
infection with parasites of the genus
Plasmodium, transmitted by mosquitos.
In addition to transmission, vital steps
in the parasite lifecycle occur in the
mosquito host. The invention offered for
licensing relates to therapeutic
compounds and related pharmaceutical
compositions that can be used in the
prevention and treatment of malaria
infection. More specifically, the
invention is drawn to compounds that
may kill sexual and mosquito stage
malaria parasites to block transmission.
Specifically claimed is the
antihistamine Ketotifen, which has
demonstrated activity blocking parasite
development in mosquitoes. Also
claimed are treatments encompassing
Ketotifen with other existing
antimalarial drugs in a combination
treatment aimed at multiple stages in
the malaria life cycle.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Prevention and treatment of malaria
infections
Competitive Advantages
• Drugs that kill sexual and mosquito
stages of the parasite are important for
preventing and/or slowing the spread of
malaria infection and ultimately for
malaria eradication.
• Primaquine, the only currently
available drug shown to block
transmission, is known to cause serious
adverse side effects.
Development Stage
• Pre-Clinical (animal data available)
Inventors: Xin-zhuan Su and Dipak
Raj (NIAID).
Publications: Eastman R.T.
Pattaradilokrat S. Raj D.K. Dixit S. Deng
B. Miura K. Yuan J. Tanaka T.Q.
Johnson R.L. Jiang H. et al. 2013. A class
E:\FR\FM\17JYN1.SGM
17JYN1
]]>Agencies
[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Notices]
[Page 32713]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14858]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute on Drug Abuse Special Emphasis Panel, July 27, 2017, 09:00
a.m. to July 27, 2017, 05:00 p.m., National Institutes of Health,
Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852
which was published in the Federal Register on June 29, 2017, 82 125 FR
2017-13696.
This meeting was amended to change the date from July 27, 2017 to
July 25, 2017. The time of the meeting remains the same. The meeting is
closed to the public.
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-14858 Filed 7-14-17; 8:45 am]
BILLING CODE 4140-01-P
